Cancer immunotherapy .net

Information on human tumours pilot studies 4

cancerimmunotherapy@yahoo.com

tumour type

Hemangiosarcoma

Results in brief: 1 patient treated, with a life expectancy of less than 3 months. Marked improvement in general condition and lived for 12 months. Research in progress

2005

Krastev Z, Koltchakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs JJL, Den Otter W. World J Gastroenterol. 2005 Sep 21; 11(35) : 5525-9. Locoregional IL-2 low dose applications for gastrointestinal tumors. AIM: To explore the feasibility of local interleukin 2 (IL-2) in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application. METHODS: Sixteen patients with stages III and IV of gastrointestinal malignancies (primary or metastatic) who were admitted to our Department of Gastroenterology were treated with locoregionally applied IL-2 in low doses. RESULTS: No major problems applying locoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. These patients suffered from colorectal carcinoma, hemangiosarcoma or hepatocellular carcinoma with liver fibrosi. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition. CONCLUSION: This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.

Krastev et al. (2005)

tumour type

Interleukin-2 (IL-2) Mechanism of IL-2 therapy of cancer Cancers sensitive to IL-2 Surgery and IL-2 Radiotherapy and IL-2 Chemotherapy and IL-2 Experts I want to co-operate (doctors) Frequently Asked Questions (FAQs)

Information for doctors Information for patients I want to support this research or  more information on the EPTI fund supporting this research

Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands